<DOC>
	<DOC>NCT02169141</DOC>
	<brief_summary>This is an open label observational pharmacokinetic drug study to evaluate Levofloxacine and Capreomycin in patients with Multidrug-Resistant Tuberculosis (MDR-TB).</brief_summary>
	<brief_title>Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients</brief_title>
	<detailed_description>Patients receive MDR-TB treatment with o.a. Levofloxacin and Capreomycin. At least one week after start of treatment, the PK samples samples will be obtained via an intravenous catheter at 0, 1, 2, 3, 4, 7, and 12 hours after intake.</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Capreomycin</mesh_term>
	<criteria>age&gt; 18yrs culture positive diagnosis of MDRTB DM2 Pregnancy allergy to IV canula material insertion of IV canula not possibele</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>MDR-TB</keyword>
	<keyword>Levofloxacin</keyword>
	<keyword>Capreomycin</keyword>
</DOC>